全关节置换术中头孢唑林安全使用的标准化多学科分诊方案
本文介绍2025年1月起实施的多学科算法分诊方案,用于有青霉素或头孢菌素过敏史的全关节置换患者。仅对特定高危史者转诊过敏检测,其余直接使用头孢唑林;实施后无患者转诊、无围手术期过敏反应。
要点
- 仅头孢唑林过敏史、严重皮肤不良反应等高危患者需术前过敏检测
- 对青霉素IgE介导反应或非头孢唑林头孢菌素非过敏反应者可直接用头孢唑林
- 该方案可减少不必要的过敏检测与二线抗菌药物使用
核心结论
- 标准化多学科分诊方案可促进有青霉素或头孢菌素过敏史患者安全使用头孢唑林,优化结局并减少不必要的医疗资源利用。
研究设计与样本
- 2025年1月,多学科团队针对接受全关节置换术且有青霉素过敏和头孢菌素过敏的患者实施新的算法分诊方案。
主要发现
- 2024年有62例患者被转诊进行过敏检测,其中仅6例被建议避免使用头孢唑林。
- 自2025年1月实施新方案以来,无患者因β-内酰胺类过敏被转诊,且无围手术期过敏反应发生。
关键数值与推荐
- 有头孢唑林过敏史、对任何头孢菌素发生过敏反应或血管性水肿、或对任何β-内酰胺类发生严重皮肤不良反应或迟发型超敏反应的患者,转诊术前过敏检测。
- 对青霉素发生IgE介导反应(包括过敏反应和血管性水肿)或对非头孢唑林头孢菌素发生非过敏反应的患者,视为无增加风险,直接接受头孢唑林而不额外检测。
临床怎么用
- 按分诊算法将患者分为需过敏检测与可直接使用头孢唑林两类,减少不必要的二线抗菌药物和术前过敏检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cefazolin is the first-line perioperative antimicrobial for total joint arthroplasty (TJA) due to its efficacy against typical skin pathogens, favorable safety profile, and cost-effectiveness. Its use reduces the risk of periprosthetic joint infection (PJI) by over 30% compared to second-line antimicrobials. Approximately 15% of patients report a penicillin allergy, although true allergy is confirmed in only 1 to 10% of these cases. Cefazolin's unique molecular structure of the R1 side chain prevents immediate immunoglobulin E (IgE)-mediated cross-reactivity with penicillin or other cephalosporins. Severe cutaneous adverse reactions or delayed hypersensitivity reactions to beta-lactam antimicrobials are rare, less understood, and involve T-cell-mediated pathways. Despite evidence suggesting no immediate IgE-mediated cross-reactivity risk, it is still common practice to use second-line antimicrobials or preoperative allergy testing in patients with a reported penicillin allergy or cephalosporin allergy. METHODS: In January 2025, a multidisciplinary team implemented a novel algorithmic triage protocol for patients with penicillin allergy and cephalosporin allergy undergoing TJA. Patients who had a history of cefazolin allergy, anaphylaxis, or angioedema to any cephalosporin or severe cutaneous adverse reactions/delayed hypersensitivity reactions to any beta-lactam were referred for preoperative allergy testing. Patients who had an IgE-mediated reaction to penicillin (including anaphylaxis and angioedema) or a nonanaphylactic reaction to a noncefazolin cephalosporin were considered at no increased risk and received cefazolin without additional testing. RESULTS: In 2024, 62 patients were referred for allergy testing, with only six being recommended to avoid cefazolin. Since the implementation of the new protocol in January 2025, no patients have been referred for beta-lactam allergies, and there have been no perioperative hypersensitivity reactions. CONCLUSIONS: This standardized, multidisciplinary approach promotes safe cefazolin administration in patients who have listed penicillin allergy or cephalosporin allergy, thereby optimizing outcomes, reducing unnecessary health care utilization, and improving care across perioperative settings.
引用
- Guido JM, Hudock NL, Frye BM, et al. Standardizing Safe Cefazolin Use in Total Joint Arthroplasty: A Multidisciplinary Triage Protocol. J Arthroplasty. 2026. PMID: 41966420. doi:10.1016/j.arth.2026.03.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。